Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis

Journal of Alzheimer's Disease

Volumn 16, Issue 4, 2009, Pages 715-729

  Lyn Cook Jr , Lascelles E ^a   Lawton, Margot ^a   Tong, Ming ^a   Silbermann, Elizabeth ^a   Longato, Lisa ^a   Jiao, Ping ^a   Mark, Princess ^a   Wands, Jack R ^a   Xu, Haiyan ^a   De La Monte, Suzanne M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid; Diabetes mellitus; High fat diet; Insulin resistance; Neurodegeneration; Non alcoholic steatohepatitis; Obesity

Indexed keywords

4 HYDROXYNONENAL; BETA ACTIN; CERAMIDE; CHOLINE ACETYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN PHOSPHODIESTERASE; TAURINE TRANSPORTER; UBIQUITIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER WEIGHT; MALE; MOUSE; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPORAL LOBE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; FAT INTAKE; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TIME;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; BRAIN; CERAMIDES; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; SERINE C-PALMITOYLTRANSFERASE; SPHINGOMYELIN PHOSPHODIESTERASE; TIME FACTORS;

EID: 67649687040     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0984     Document Type: Article

References (89)

1. Rector RS, Thyfault JP, Wei Y, Ibdah JA (2008) Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14, 185-192. (Pubitemid 351314297)
2. Pradhan A (2007) Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 65, S152-156.
3. Launer LJ (2007) Next steps in Alzheimer's disease research: interaction between epidemiology and basic science. Curr Alzheimer Res 4, 141-143.
4. Wang XP, Ding HL (2008) Alzheimer's disease: epidemiology, genetics, and beyond. Neurosci Bull 24, 105-109.
5. Delgado JS (2008) Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med 19, 75-82.
6. Nugent C, Younossi ZM (2007) Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 4, 432-441. (Pubitemid 47208893)
7. Pasquier F, Boulogne A, Leys D, Fontaine P (2006) Diabetes mellitus and dementia. Diabetes Metab 32, 403-414.
8. Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat H, Erkinjuntti T, Fazekas F, Hennerici M, O'Brien J, Pantoni L, Salvadori E, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A, Inzitari D (2007) Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 78, 1325-1330. (Pubitemid 350221411)
9. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11, 721-736. (Pubitemid 44141805)
10. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268. (Pubitemid 43312053)
11. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80. (Pubitemid 40387185)
12. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152. (Pubitemid 46557503)
13. Craft S (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20, 298-301.
14. Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP, McEwen BS (2005) Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci 119, 1389-1395. (Pubitemid 41598751)
15. Winocur G, Greenwood CE (2005) Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol Aging 26 Suppl 1, 46-49. (Pubitemid 41739425)
16. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
17. Weinstock M, Shoham S (2004) Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 111, 347-366. (Pubitemid 38316610)
18. Nitta A, Murai R, Suzuki N, Ito H, Nomoto H, Katoh G, Furukawa Y, Furukawa S (2002) Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol Teratol 24, 695-701. (Pubitemid 35013529)
19. Hoyer S, Lannert H, Noldner M, Chatterjee SS (1999) Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 106, 1171-1188. (Pubitemid 30009214)
20. Biju MP, Paulose CS (1998) Brain glutamate dehydrogenase changes in streptozotocin diabetic rats as a function of age. Biochem Mol Biol Int 44, 1-7.
21. de la Monte SM, Tong M, Lester-Coll N, Plater M, Jr.,Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10, 89-109. (Pubitemid 44401370)
22. Haan MN (2006) Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2, 159-166. (Pubitemid 43307392)
23. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, Degroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates {beta}-amyloid in early AD. Neurology 70, 440-448.
24. Landreth G (2007) Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res 4, 159-164. (Pubitemid 46557505)
25. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frolich L, Craft S (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 27, 38-41. (Pubitemid 41627948)
26. Reger MA, Watson GS, Frey WH, 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27, 451-458.
27. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199, 265-273. (Pubitemid 43928978)
28. Nicolls MR (2004) The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 1, 47-54.
29. Yeh MM, Brunt EM (2007) Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128, 837-847. (Pubitemid 350133997)
30. Marchesini G, Marzocchi R (2007) Metabolic syndrome and NASH. Clin Liver Dis 11, 105-117, ix.
31. Papandreou D, Rousso I, Mavromichalis I (2007) Update on non-alcoholic fatty liver disease in children. Clin Nutr 26, 409-415. (Pubitemid 47091479)
32. Pessayre D (2007) Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22 Suppl 1, S20-27.
33. Wei Y, Rector RS, Thyfault JP, Ibdah JA (2008) Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 14, 193-199. (Pubitemid 351314298)
34. Qiu C, De Ronchi D, Fratiglioni L (2007) The epidemiology of the dementias: an update. Curr Opin Psychiatry 20, 380-385.
35. Whitmer RA (2007) Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 7, 373-380. (Pubitemid 47422778)
36. Haan MN, Wallace R (2004) Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 25, 1-24.
37. Luchsinger JA, Mayeux R (2004) Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 6, 261-266. (Pubitemid 39359464)
38. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64, 570-575. (Pubitemid 46588347)
39. Launer LJ (2005) Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep 5, 59-63.
40. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, Montero JL, Costan G, Marchal T, Membrives A, Gallardo-Valverde JM, Munoz-Castaneda JR, Arevalo E, De la Mata M, Muntane J (2007) IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17, 493-503. (Pubitemid 46850189)
41. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP (2007) Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102, 399-408. (Pubitemid 46160554)
42. Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC (2006) Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg 16, 1584-1593. (Pubitemid 46032811)
43. Nobili V, Manco M (2007) Measurement of advanced glycation end products may change NASH management. J Gastroenterol Hepatol 22, 1354-1355. (Pubitemid 47274584)
44. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F (2008) Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 283, 13538-13548.
45. Summers SA (2006) Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45, 42-72.
46. Alessenko AV, Bugrova AE, Dudnik LB (2004) Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans 32, 144-146.
47. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH, Jr., Futerman AH (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283, 5677-5684.
48. Nakane M, Kubota M, Nakagomi T, Tamura A, Hisaki H, Shimasaki H, Ueta N (2000) Lethal forebrain ischemia stimulates sphingomyelin hydrolysis and ceramide generation in the gerbil hippocampus. Neurosci Lett 296, 89-92.
49. Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 32, 845-856. (Pubitemid 46481322)
50. Adibhatla RM, Hatcher JF (2008) Altered Lipid Metabolism in Brain Injury and Disorders. Subcell Biochem 48, nihpa41041.
51. Liu B, Obeid LM, Hannun YA (1997) Sphingomyelinases in cell regulation. Semin Cell Dev Biol 8, 311-322.
52. Reynolds CP, Maurer BJ, Kolesnick RN (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206, 169-180. (Pubitemid 38317287)
53. Mizutani Y, Kihara A, Igarashi Y (2005) Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 390, 263-271. (Pubitemid 41192252)
54. Mari M, Fernandez-Checa JC (2007) Sphingolipid signalling and liver diseases. Liver Int 27, 440-450.
55. Paul P, Kamisaka Y, Marks DL, Pagano RE (1996) Purification and characterization of UDP-glucose:ceramide glucosyltransferase from rat liver Golgi membranes. J Biol Chem 271, 2287-2293. (Pubitemid 26047821)
56. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Jarvinen H (2008) Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294, G1281-1287.
57. Jennemann R, Sandhoff R, Wang S, Kiss E, Gretz N, Zuliani C, Martin-Villalba A, Jager R, Schorle H, Kenzelmann M, Bonrouhi M, Wiegandt H, Grone HJ (2005) Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci U S A 102, 12459-12464. (Pubitemid 41266381)
58. Han MS, Park SY, Shinzawa K, Kim S, Chung KW, Lee JH, Kwon CH, Lee KW, Park CK, Chung WJ, Hwang JS, Yan JJ, Song DK, Tsujimoto Y, Lee MS (2008) Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 49, 84-97.
59. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287, G1035-1043. (Pubitemid 39423696)
60. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79, 502-509.
61. Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, Erensoy A (2006) Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006, 34295. (Pubitemid 44826824)
62. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK (2004) Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99, 1946-1952. (Pubitemid 39421237)
63. Moroz N, Tong M, Longato L, Xu H, de la Monte SM (2008) Limited Alzheimer-type neurodegeneration in experimental obesity and Type 2 diabetes mellitus. J Alzheimers Dis 15, 29-44.
64. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821-1830. (Pubitemid 38063705)
65. Yeon JE, Califano S, Xu J, Wands JR, De La Monte SM (2003) Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology 38, 703-714. (Pubitemid 37052157)
66. Xu J, Eun Yeon J, Chang H, Tison G, Jun Chen G,Wands JR, De La Monte SM (2003) Ethanol impairs insulin-stimulated neuronal survival in the developing brain: Role of PTEN phosphatase. J Biol Chem 278, 26929-26937. (Pubitemid 36876845)
67. Cohen AC, Tong M, Wands JR, de la Monte SM (2007) Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res 31, 1558-1573. (Pubitemid 47319658)
68. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, Johnson MD (2001) Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitr Mol Toxicol 14, 177-190. (Pubitemid 34326670)
69. Fowler SD, Greenspan P (1985) Application of Nile red, a fluorescent hydrophobic probe, for the detection of neutral lipid deposits in tissue sections: comparison with oil red O. J Histochem Cytochem 33, 833-836.
70. Greenspan P, Fowler SD (1985) Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res 26, 781-789. (Pubitemid 15046441)
71. Winzell MS, Magnusson C, Ahren B (2007) Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice. Metabolism 56, 122-128. (Pubitemid 44855020)
72. Cong WN, Tao RY, Tian JY, Liu GT, Ye F (2008) The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 82, 983-990.
73. Yoshimatsu M, Terasaki Y, Sakashita N, Kiyota E, Sato H, van der Laan LJ, Takeya M (2004) Induction of macrophage scavenger receptor MARCO in nonalcoholic steatohepatitis indicates possible involvement of endotoxin in its pathogenic process. Int J Exp Pathol 85, 335-343. (Pubitemid 39647362)
74. Kirsch R, Clarkson V, Verdonk RC, Marais AD, Shephard EG, Ryffel B, de la MHP (2006) Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol 21, 174-182.
75. de la Monte SM (1989) Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 25, 450-459.
76. Elwing JE, Lustman PJ, Wang HL, Clouse RE (2006) Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med 68, 563-569.
77. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA (2007) Lipid mediators of insulin resistance. Nutr Rev 65, S39-46.
78. Kraegen EW, Cooney GJ (2008) Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 19, 235-241. (Pubitemid 351653560)
79. Wang G, Silva J, Dasgupta S, Bieberich E (2008) Long-chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia 56, 449-456. (Pubitemid 351212953)
80. Arboleda G, Huang TJ, Waters C, Verkhratsky A, Fernyhough P, Gibson RM (2007) Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci 25, 3030-3038. (Pubitemid 46888810)
81. Gallou-Kabani C, Vige A, Gross MS, Rabes JP, Boileau C, Larue-Achagiotis C, Tome D, Jais JP, Junien C (2007) C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity (Silver Spring) 15, 1996-2005. (Pubitemid 47402231)
82. Ito M, Suzuki J, Sasaki M, Watanabe K, Tsujioka S, Takahashi Y, Gomori A, Hirose H, Ishihara A, Iwaasa H, Kanatani A (2006) Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol Res 34, 92-98. (Pubitemid 43137557)
83. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW, 2nd, De-Furia J, Jick Z, Greenberg AS, Obin MS (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56, 2910-2918.
84. Diehl AM (2005) Lessons from animal models of NASH. Hepatol Res 33, 138-144.
85. Solis Herruzo JA, Garcia Ruiz I, Perez Carreras M, Munoz Yague MT (2006) Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev Esp Enferm Dig 98, 844-874. (Pubitemid 350259114)
86. Soscia SJ, Tong M, Xu XJ, Cohen AC, Chu J, Wands JR, de la Monte SM (2006) Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol Life Sci 63, 2039-2056. (Pubitemid 44359744)
87. Lopes-Cardozo M, Sykes JE, Van der Pal RH, van Golde LM (1989) Development of oligodendrocytes. Studies of rat glial cells cultured in chemically-defined medium. J Dev Physiol 12, 117-127. (Pubitemid 20082731)
88. Broughton SK, Chen H, Riddle A, Kuhn SE, Nagalla S, Roberts CT, Jr., Back SA (2007) Large-scale generation of highly enriched neural stem-cell-derived oligodendroglial cultures: maturation-dependent differences in insulin-like growth factor-mediated signal transduction. J Neurochem 100, 628-638. (Pubitemid 46095614)
89. Chesik D, De Keyser J, Wilczak N (2008) Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. J Mol Neurosci 35, 81-90.